Annual report pursuant to Section 13 and 15(d)

Note 15 - Segments (Tables)

v3.23.1
Note 15 - Segments (Tables)
12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Year Ended December 31, 2022

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Sales revenue:

                               

United States

  $     $     $     $  

International

    14,645                   14,645  

Grant and other revenue

    51,007                   51,007  

Total revenue

    65,652                   65,652  

Cost of revenue

    1,941                   1,941  

Adjustments for expired and expiring inventory

    183,006                   183,006  

Research and development expenses

    5,501,134       468,640             5,969,774  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          4,530       7,861,477       7,866,007  

Depreciation and amortization (2)

    29,387             66,432       95,819  

Loss from operations (3)

    (5,649,816

)

    (473,170

)

    (7,927,909

)

    (14,050,895

)

Other expense, net (4)

                (1,126,261 )     (1,126,261

)

Net loss

    (5,649,816

)

    (473,170

)

    (9,054,170

)

    (15,177,156

)

Total assets, net of depreciation and amortization:                                

United States

  $ 610     $     $ 3,817,195     $ 3,817,805  

International

    539,188             14,613       553,801  

Capital expenditures

    54,650             8,436       63,086  

Year Ended December 31, 2021

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Royalty revenue

  $     $     $     $  

License revenue

    45,615                   45,615  

Grant and other revenue

    485,898                   485,898  

Total revenue

    531,513                   531,513  

Research and development expenses, excluding depreciation and amortization

    4,488,177       653,733             5,141,910  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          4,438       7,368,623       7,373,061  

Depreciation and amortization (2)

    24,162             52,792       76,954  

Loss from operations (3)

    (3,980,826

)

    (658,171

)

    (7,421,415

)

    (12,060,412

)

Other income (4)

                345,524      

345,524

 

Provision for income taxes

    (5,452

)

    (901

)

    (9,690 )     (16,043 )

Net loss

    (3,986,278

)

    (659,072

)

    (7,085,581

)

    (11,730,931

)

Total assets, net of depreciation and amortization:                                

United States

  $ 107,931     $     $ 6,326,031     $ 6,433,962  

International

    210,281             590       210,871  

Capital expenditures

                25,218       25,218